Drug Profile
Dilpacimab - AbbVie
Alternative Names: ABT-165; DVD-Ig ABT-165Latest Information Update: 25 Oct 2022
Price :
$50
*
At a glance
- Originator AbbVie
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action DLL4 protein inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I Solid tumours
Most Recent Events
- 25 Oct 2022 Phase-I development in Solid tumours (Late-stage disease, Combination therapy) is ongoing in USA (IV)
- 25 Oct 2022 Phase-I development in Solid tumours (Late-stage disease, Monotherapy) is ongoing in USA (IV)
- 28 Sep 2022 AbbVie completes a phase I/Ib trial in Solid tumours (Late-stage disease, Combination therapy) in USA (IV) (NCT01946074)